The Beginning of Ending Hepatitis C Virus: A Summary of the 26th International Symposium on Hepatitis C Virus and Related Viruses
Eui-Cheol Shin,
Ji Won Han,
Wonseok Kang,
Takanobu Kato,
Seong-Jun Kim,
Jin Zhong,
Seungtaek Kim,
Su-Hyung Park,
Pil Soo Sung,
Koichi Watashi,
Jun Yong Park,
Marc P. Windisch,
Jong-Won Oh,
Takaji Wakita,
Kwang-Hyub Han,
Sung Key Jang
Affiliations
Eui-Cheol Shin
Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon 34141, Korea
Ji Won Han
Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon 34141, Korea
Wonseok Kang
Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Korea
Takanobu Kato
Department of Virology II, National Institute of Infectious Diseases, Tokyo 162-8640, Japan
Seong-Jun Kim
Center for Convergent Research of Emerging Virus Infection, Korea Research Institute of Chemical Technology, Daejeon 34114, Korea
Jin Zhong
Unit of Viral Hepatitis, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai 200031, China
Seungtaek Kim
Zoonotic Virus Laboratory, Institut Pasteur Korea, Seongnam 13488, Korea
Su-Hyung Park
Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon 34141, Korea
Pil Soo Sung
Division of Gastroenterology and Hepatology, Department of Internal Medicine, College of Medicine, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul 06591, Korea
Koichi Watashi
Department of Virology II, National Institute of Infectious Diseases, Tokyo 162-8640, Japan
Jun Yong Park
Department of Internal Medicine, Yonsei University College of Medicine, Seoul 03722, Korea
Marc P. Windisch
Applied Molecular Virology Laboratory, Institut Pasteur Korea, Seongnam 13488, Korea
Jong-Won Oh
Department of Biotechnology, Yonsei University, Seoul 03722, Korea
Takaji Wakita
Department of Virology II, National Institute of Infectious Diseases, Tokyo 162-8640, Japan
Kwang-Hyub Han
Department of Internal Medicine, Yonsei University College of Medicine, Seoul 03722, Korea
Sung Key Jang
Department of Life Sciences, Pohang University of Science and Technology, Pohang 37673, Korea
Hepatitis C virus (HCV) infects ~71 million people worldwide, and 399,000 people die annually due to HCV-related liver cirrhosis and hepatocellular carcinoma. The use of direct-acting antivirals results in a sustained virologic response in >95% of patients with chronic HCV infection. However, several issues remain to be solved to eradicate HCV. At the 26th International Symposium on Hepatitis C Virus and Related Viruses (HCV2019) held in Seoul, South Korea, October 5−8, 2019, virologists, immunologists, and clinical scientists discussed these remaining issues and how we can achieve the elimination of HCV.
